NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/07/2025
Back to search
Official data from USPTO
MINDLIGHT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
10/08/2025
Classification
Registered
Trademark type
Word
Nice classes
44
Filing date
06/05/2024
Registration date
10/07/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/07/2025
Last transaction
10/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
11/01/2024
First use in commerce
11/01/2024
Drawing code
4
Owner type
03
Owner location
Albuquerque, NM
Examiner
MMEJE,OBIEZE GINIKANWA
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Circular Genomics, Inc.
Representatives
David S. Kerr Berg Hill Greenleaf Ruscitti LLP
Technical classification
Nice Classes
Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 44
Medical laboratory analysis services relating to the treatment of personsdetecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of personsdetecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of personsnamely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patientsdetecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patientsdetecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of patientsdetecting circular RNA biomarkers in blood samples for the diagnosis of a major depression disorder; Medical diagnostic testingmonitoring and reporting servicesnamely diagnostic testingmonitoring and reporting of circular RNA biomarkers for medical purposes; Medical diagnostic testingmonitoring and reporting servicesnamely diagnostic testingmonitoring and reporting of circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical diagnostic testingmonitoring and reporting servicesnamely diagnostic testingmonitoring and reporting of circular RNA biomarkers in blood samples for major depressive disorders (MDD); Medical diagnostic testingmonitoring and reporting servicesnamely diagnostic testingmonitoring and reporting of circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patientsdetecting circular RNA biomarkers in blood samples for predicting patient response to selective serotonin reuptake inhibitor (SSRI) and disease prognosis based on SSRI treatment; and Medical diagnostic testingmonitoring and reporting servicesnamely diagnostic testingmonitoring and reporting of circular RNA biomarkers in blood samples for predicting patient response to SSRI for treatment of major depressive disorder (MDD) and predicting disease prognosis following treatment
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
10/07/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/15/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/15/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/02/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
07/01/2025
IUAF
USE AMENDMENT FILED
03/28/2025
EISU
TEAS STATEMENT OF USE RECEIVED
03/28/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/25/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/28/2025
PUBO
PUBLISHED FOR OPPOSITION
01/28/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/22/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/07/2025
DOCK
ASSIGNED TO EXAMINER
12/18/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/17/2024
NWAP
NEW APPLICATION ENTERED
06/05/2024
Continuous trademark protection
Get notified about every new filing that threatens MINDLIGHT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.